123 related articles for article (PubMed ID: 27302903)
21. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
[TBL] [Abstract][Full Text] [Related]
22. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
Sapra P; Zhao H; Mehlig M; Malaby J; Kraft P; Longley C; Greenberger LM; Horak ID
Clin Cancer Res; 2008 Mar; 14(6):1888-96. PubMed ID: 18347192
[TBL] [Abstract][Full Text] [Related]
23. TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells.
Liu YP; Chen HL; Tzeng CC; Lu PJ; Lo CW; Lee YC; Tseng CH; Chen YL; Yang CN
Breast Cancer Res Treat; 2013 Apr; 138(2):383-93. PubMed ID: 23430225
[TBL] [Abstract][Full Text] [Related]
24. [Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].
Xu JM; Li YM; Wang Y; Zhao CH; Yuan SJ; Yang WW; Li ZQ; Han Y; Azzariti A; Paradiso A
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):578-82. PubMed ID: 17236550
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, characterization, and antitumor evaluation of the albumin-SN38 conjugate.
Yao Y; Su X; Xie Y; Wang Y; Kang T; Gou L; Yi C; Yang J
Anticancer Drugs; 2013 Mar; 24(3):270-7. PubMed ID: 23233044
[TBL] [Abstract][Full Text] [Related]
26. DNA topoisomerase I content of a pair of human melanoma cell lines with very different radiosensitivities correlates with their in vitro sensitivities to camptothecin.
Ng CE; Cybulski SE; Bussey AM; Aubin RA; Raaphorst GP
Anticancer Res; 1998; 18(4C):3119-26. PubMed ID: 9713520
[TBL] [Abstract][Full Text] [Related]
27. Novel 20(S)-sulfonylamidine derivatives of camptothecin and the use thereof as a potent antitumor agent: a patent evaluation of WO2015048365 (A1).
Beretta GL; Zaffaroni N; Varchi G
Expert Opin Ther Pat; 2016 May; 26(5):637-42. PubMed ID: 26814056
[TBL] [Abstract][Full Text] [Related]
28. Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines.
Hamilton G; Klameth L; Rath B; Thalhammer T
Molecules; 2014 Feb; 19(2):2077-88. PubMed ID: 24549232
[TBL] [Abstract][Full Text] [Related]
29. Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects.
Du Y; Zhang W; He R; Ismail M; Ling L; Yao C; Fu Z; Li X
Bioorg Med Chem; 2017 Jun; 25(12):3247-3258. PubMed ID: 28465086
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and preliminary bioevaluation of novel E-ring modified acetal analog of camptothecin as cytotoxic agents.
Zhu L; Zhuang C; Lei N; Guo Z; Sheng C; Dong G; Wang S; Zhang Y; Yao J; Miao Z; Zhang W
Eur J Med Chem; 2012 Oct; 56():1-9. PubMed ID: 23084702
[TBL] [Abstract][Full Text] [Related]
31. Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968.
Pisano C; De Cesare M; Beretta GL; Zuco V; Pratesi G; Penco S; Vesci L; Foderà R; Ferrara FF; Guglielmi MB; Carminati P; Dallavalle S; Morini G; Merlini L; Orlandi A; Zunino F
Mol Cancer Ther; 2008 Jul; 7(7):2051-9. PubMed ID: 18645015
[TBL] [Abstract][Full Text] [Related]
32. [Screening of DNA topoisomerase inhibitors].
Andoh T; Umemura K; Yanase K; Takahashi N
Gan To Kagaku Ryoho; 2004 Apr; 31(4):495-500. PubMed ID: 15114689
[TBL] [Abstract][Full Text] [Related]
33. Structural insight of DNA topoisomerases I from camptothecin-producing plants revealed by molecular dynamics simulations.
Sirikantaramas S; Meeprasert A; Rungrotmongkol T; Fuji H; Hoshino T; Sudo H; Yamazaki M; Saito K
Phytochemistry; 2015 May; 113():50-6. PubMed ID: 25733498
[TBL] [Abstract][Full Text] [Related]
34. Lipid nanoparticles loaded with 7-ethyl-10-hydroxycamptothecin-phospholipid complex: in vitro and in vivo studies.
Liu H; Lu H; Liao L; Zhang X; Gong T; Zhang Z
Drug Deliv; 2015; 22(6):701-9. PubMed ID: 24625262
[TBL] [Abstract][Full Text] [Related]
35. Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues.
Lavergne O; Lesueur-Ginot L; Pla Rodas F; Kasprzyk PG; Pommier J; Demarquay D; Prévost G; Ulibarri G; Rolland A; Schiano-Liberatore AM; Harnett J; Pons D; Camara J; Bigg DC
J Med Chem; 1998 Dec; 41(27):5410-9. PubMed ID: 9876111
[TBL] [Abstract][Full Text] [Related]
36. Synergistic effects of topoisomerase I inhibitor, SN38, on Fas-mediated apoptosis.
Cao Y; Jin ZX; Tong XP; Yue S; Sakai T; Kawanami T; Sawaki T; Miki M; Iwao H; Nakajima A; Masaki Y; Fukushima Y; Fujita Y; Nakajima H; Okazaki T; Umehara H
Anticancer Res; 2010 Oct; 30(10):3911-7. PubMed ID: 21036702
[TBL] [Abstract][Full Text] [Related]
37. Total synthesis of 7-ethyl-10-hydroxycamptothecin (SN38) and its application to the development of C18-functionalized camptothecin derivatives.
Yao YS; Liu JL; Xi J; Miu B; Liu GS; Wang S; Meng L; Yao ZJ
Chemistry; 2011 Sep; 17(37):10462-9. PubMed ID: 21850716
[TBL] [Abstract][Full Text] [Related]
38. In vitro sensitivity of fresh ovarian carcinoma specimens to CPT-11 (irinotecan).
O'meara AT; Sevin BU
Gynecol Oncol; 1999 Feb; 72(2):143-7. PubMed ID: 10021292
[TBL] [Abstract][Full Text] [Related]
39. Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
Pastorino F; Loi M; Sapra P; Becherini P; Cilli M; Emionite L; Ribatti D; Greenberger LM; Horak ID; Ponzoni M
Clin Cancer Res; 2010 Oct; 16(19):4809-21. PubMed ID: 20702613
[TBL] [Abstract][Full Text] [Related]
40. The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.
Di Francesco AM; Riccardi A; Barone G; Rutella S; Meco D; Frapolli R; Zucchetti M; D'Incalci M; Pisano C; Carminati P; Riccardi R
Biochem Pharmacol; 2005 Oct; 70(8):1125-36. PubMed ID: 16139802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
